Pancreatic Ca

Oncology·MeSH: Carcinoma, Non-Small-Cell Lung

Prevalence

8.0 / 100K

Incidence

13.1 / 100K/yr

110 drugs in development·58 companies·0 clinical trials

Drug Pipeline by Phase

Approved(1)
DrugCompany
ABRAXANEImmunityBio, Inc. (IBRX)
Phase 3(23)
DrugCompany
atebimetinibImmuneering Corp (IMRX)
bcg+n-803. )ImmunityBio, Inc. (IBRX)
BNT321 0.5 mg/kgBioNTech SE (BNTX)
ChemotherapyENANTA PHARMACEUTICALS INC (ENTA)
fludarabineFilana Therapeutics Inc. (FLNA)
FOLFIRINOXIGM Biosciences, Inc. (IGMS)
FOLFIRINOX chemotherapyMerus N.V. (MRUS)
glufosfamideBullfrog AI Holdings Inc. (BFRG)
gnpImmuneering Corp (IMRX)
iagRenovoRx, Inc. (RNXT)
Investigator's Choice of ChemotherapyENANTA PHARMACEUTICALS INC (ENTA)
ivospeminPANBELA THERAPEUTICS, INC. (SNBP)
lanreotideGH Research PLC (GHRS)
leucovorinREVOLUTION MEDICINES, INC. (RVMD)
LeucovorinTango Therapeutics, Inc. (TNGX)
mgnpImmuneering Corp (IMRX)
N-803ImmunityBio, Inc. (IBRX)
Neoadjuvant olaparibENANTA PHARMACEUTICALS INC (ENTA)
Platinum chemotherapyENANTA PHARMACEUTICALS INC (ENTA)
SetidegrasibTango Therapeutics, Inc. (TNGX)
SetidegrasibMerus N.V. (MRUS)
Sintilimab injectionKYNTRA BIO INC. (KYNB)
tak-500Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK)
Phase 2(27)
DrugCompany
AB680Arcus Biosciences, Inc. (RCUS)
ABV-1703ABVC BIOPHARMA, INC. (ABVC)
ampligenAIM ImmunoTech Inc. (AIM)
Ampligen (rintatolimod)AIM ImmunoTech Inc. (AIM)
Anti-EGFRMerus N.V. (MRUS)
Anti-PD-1 monoclonal antibodyMerus N.V. (MRUS)
cyt-0851Cyteir Therapeutics, Inc. (CYT)
FOLFIRIMerus N.V. (MRUS)
FolfirinoxMerus N.V. (MRUS)
FolfirinoxKYNTRA BIO INC. (KYNB)
folfirinox aloneSalspera, Inc. (TKVA)
LeucovorinImmunityBio, Inc. (IBRX)
mFOLFIRINOXKYNTRA BIO INC. (KYNB)
mFOLFIRINOXBioNTech SE (BNTX)
mFOLFIRINOXMerus N.V. (MRUS)
mFOLFIRINOX infusionMerus N.V. (MRUS)
mFOLFIRINOX Treatment RegimenKYNTRA BIO INC. (KYNB)
nal-IRI,5-fu,LV, benmelstobart, anlotinibMerus N.V. (MRUS)
OlaparibENANTA PHARMACEUTICALS INC (ENTA)
ot-101Oncotelic Therapeutics, Inc. (OTLC)
PD-L1 t-haNKImmunityBio, Inc. (IBRX)
regorafenibIncyte Corp. (INCY)
RintatolimodAIM ImmunoTech Inc. (AIM)
rucosopasem manganeseGalera Therapeutics, Inc. (GRTX)
salmonella-il2Salspera, Inc. (TKVA)
sig12d-loderSilexion Therapeutics Corp (SLXN)
TripegfilgrastimKYNTRA BIO INC. (KYNB)
Phase 1(20)
DrugCompany
ADCT-601ADC Therapeutics SA (ADCT)
APX005MArcus Biosciences, Inc. (RCUS)
APX005MIGM Biosciences, Inc. (IGMS)
BNT321 DL 2BioNTech SE (BNTX)
BP1001-ABIO-PATH HOLDINGS, INC. (BPTH)
CT-1119Carisma Therapeutics Inc. (CARM)
FOLFIRIArcus Biosciences, Inc. (RCUS)
fpa150FIVE PRIME THERAPEUTICS, INC. (FPRX)
individualized anti-tumor new antigen iNeo-Vac-R01 injectionKYNTRA BIO INC. (KYNB)
modified folfirinoxAMGEN INC (AMGN)
mvt-5873MABVAX THERAPEUTICS HOLDINGS, INC. (MBVX)
nelitolimodTriSalus Life Sciences Inc. (TLSI)
pritumumabNascent Biotech Inc. (NBIO)
qn-302AIxCrypto Holdings, Inc. (AIXC)
rmc-6236AMGEN INC (AMGN)
sotevtamabImmunityBio, Inc. (IBRX)
srf617Surface Oncology, Inc. (SURF)
sy-5609Syros Pharmaceuticals, Inc. (SYRS)
TROP2-CAR-NKFilana Therapeutics Inc. (FLNA)
zabadinostatImmunityBio, Inc. (IBRX)

Compare drugs

ABRAXANE vs atebimetinibABRAXANE vs bcg+n-803. )ABRAXANE vs BNT321 0.5 mg/kg

Frequently asked questions

How many drugs are in development for Pancreatic Ca?

BioSniper tracks 110 drugs in development for Pancreatic Ca across 58 companies.

What is the prevalence of Pancreatic Ca?

The estimated prevalence of Pancreatic Ca is approximately 8.0 per 100,000 population.

Deep-dive into Pancreatic Ca

Full trial data, competitive analysis, and AI-powered pipeline tracking.

Start Free Analysis